The financial valuation of a drug that is still under development is required for various purposes. The risk-adjusted net present value (r-NPV) method, which recently emerged in the biotech industry, uses the development attrition rate as a discount factor to reflect risk during each development...

The implacable list of diversification indices allows a wide range of selection opportunities for the researchers. The absence of consensus on the selection of suitable technology diversification index, however, may lead to a lack of objectivity with ample grounds. In this study, we focus on the...